Metabolic risk conferred by adiposity may be due to associated risk factor clustering.
O BESITY IS A rapidly growing health problem in the United States, conferring substantial excess risk for morbidity and mortality, especially from type 2 diabetes and atherosclerotic cardiovascular disease (CVD) (1, 2) . Obesity is a complex disorder, where genetic predisposition interacts with environmental exposures to produce a heterogeneous phenotype (3) . Body mass index (BMI) has consistently been associated with adverse health outcomes, but subphenotypes of obesity have been recognized that appear to deviate from the apparent dose-response relationship between BMI and its consequences. Ruderman and others (4 -8) identified metabolically obese normal-weight (MONW) individuals who, despite having a normal-weight BMI, demonstrate metabolic disturbances typical of obese individuals. These disturbances include insulin resistance (IR) and increased levels of central adiposity, low levels of high-density lipoprotein-cholesterol (HDL-C) and elevated levels of triglycerides, impaired fasting glucose, and hypertension. This clustering of risk factors has been called the metabolic syndrome (MetS) (9) . Others have described metabolically healthy obese (MHO) individuals, who, despite having BMI exceeding 30 kg/m 2 , are relatively insulin sensitive and lack most of the metabolic abnormalities typical of obese individuals (10 -13) . MONW and MHO individuals are interesting because these phenotypes separate obesity from its usual metabolic consequences, offering insight into risks associated with risk factor clustering or IR that are largely independent of overall obesity (MONW) or risks associated with obesity that are largely independent of adiposity's intermediate metabolic abnormalities (MHO).
Characteristics of BMI-metabolic risk subphenotypes have been described in selected study samples, but their prevalence in a community-based sample is not well established. Furthermore, both obesity and MetS or IR are strong risk factors for type 2 diabetes and CVD, but whether elevated BMI in their absence confers risk for type 2 diabetes or CVD is uncertain. In this study, we categorized subjects of the Framingham Offspring Study (FOS) into normal-weight, overweight, and obese BMI categories and with or without risk factor clustering (defined by the presence of MetS) or IR (using the homeostasis model) to describe the community prevalence of obesity subphenotypes. We then followed subjects for the development of type 2 diabetes or CVD to test the hypothesis that, relative to normal-weight individuals without MetS or IR, obese subjects without MetS or IR (resembling the MHO phenotype) were not at substantially increased risk, normal-weight individuals with MetS or IR were at intermediate risk (resembling MONW), and obese individuals with MetS or IR were at the highest risk for development of type 2 diabetes and/or CVD.
Subjects and Methods

Study sample
The FOS is a community-based prospective observational study of CVD (14) . Offspring subjects are white, of mixed European ancestry. During the fifth examination cycle (1991) (1992) (1993) (1994) (1995) , 3799 participants fasted overnight and had a standardized medical examination, including a 2-h oral glucose tolerance test (OGTT). A total of 2902 subjects provided data for the present analysis, after exclusion of 659 with diabetes or CVD at the baseline exam, and 238 with missing baseline BMI or MetS characteristics. Subjects were followed from baseline over a mean of 6.8 yr for the incidence of diabetes and a mean of 11.4 yr for first CVD events. The Institutional Review Board of Boston University approved the study protocol, and all subjects gave informed consent at each examination.
Exposure and outcome definitions
We defined diabetes at the baseline exam as a fasting plasma glucose (FPG) level more than or equal to 7.0 mmol/liter, a 2-h OGTT glucose of more than or equal to 11.1 mmol/liter, or current use of hypoglycemic drug therapy. We defined diabetes at follow-up as development of a FPG level more than or equal to 7.0 mmol/liter or new use of hypoglycemic drug therapy. Over 98% of diabetes among Framingham Offspring is type 2 diabetes (15). We defined baseline and follow-up CVD by standard Framingham Heart Study criteria as any of the following: newonset angina, fatal and nonfatal myocardial infarction or stroke, transient ischemic attack, heart failure, or intermittent claudication (16) .
We defined MetS using the Third Report of the National Cholesterol Education Program's Adult Treatment Panel (ATP3) criteria as any three or more of: FPG, 5.6 -6.9 mmol/liter; waist circumference more than 102 cm (in men) or more than 88 cm (in women); fasting triglycerides more than or equal to 1.7 mmol/liter; high-density lipoprotein-cholesterol (HDL-C) less than 1.0 mmol/liter (in men) or less than 1.3 mmol/liter (in women); and blood pressure (BP) more than or equal to 130/85 mm Hg or current treatment for hypertension (9) . We used the homeostasis model [(fasting glucose ϫ fasting insulin)/22.5)] and defined IR as a homeostasis model assessment (HOMA)-IR level in the top quartile of the distribution among subjects without diabetes (17, 18) .
We measured height, weight, and waist circumference with the subject standing. We calculated BMI as weight in kilograms divided by the square of height in meters. We used BP as the mean of two measurements after the subject had been seated for at least 5 min. We considered subjects who reported smoking cigarettes regularly during the year before the exam to be current smokers. We estimated low-density lipoprotein-cholesterol (LDL-C) indirectly using the Friedewald formula (19) . We based a positive parental history of diabetes on self-report of diabetes in one or both parents (20) . We defined impaired glucose tolerance as a 2-h OGTT glucose level of 7.8 -11.0 mmol/liter. Laboratory methods for glucose, insulin, and lipid assays have been published previously (21) . The Framingham laboratory participates in the Centers for Disease Control lipoprotein cholesterol laboratory standardization program. Assay coefficients of variation were less than 3% for glucose and less than 10% for insulin.
Statistical analysis
We used the Mantel-Haenszel statistic or ANOVA to test trends in baseline characteristics across BMI-MetS or IR categories. We classified subjects into three BMI categories (normal weight, Ͻ25 kg/m 2 ; overweight, 25-29.9 kg/m 2 ; and obese, Ն30 kg/m 2 ) and with or without MetS or, in separate analyses, IR. Subjects were followed from baseline through the seventh exam (1998 -2001) for diabetes and through December, 2004 for CVD events. Risk for diabetes or CVD was examined in separate analyses. We calculated the cumulative incidence of diabetes or CVD as the number of diabetes or CVD events divided by the number of subjects at risk in each category at baseline. For diabetes incidence, we used the exam visit date that a new case of diabetes was identified as the date of diagnosis. For CVD events, we used the actual date of the event as the date of diagnosis and for subjects without events, the date of their last follow-up exam as the censoring date. We used hazard ratios from proportional hazards regression models (accounting for interval censoring for diabetes events) to estimate relative risks (RRs) and 95% confidence intervals (CIs) for incident diabetes or CVD conditioned on baseline BMI and MetS or IR categories. Models were adjusted for age and sex, and we used those with BMI less than 25 kg/m 2 and without MetS or IR as the referent groups. Multivariable models predicting incident diabetes included covariates for age, sex, parental history of diabetes, and impaired glucose tolerance. Multivariable models predicting incident CVD included covariates for age, sex, LDL-C level, and smoking. We conducted a subsidiary analysis of CVD events that excluded incident cases of diabetes to ensure that risk was not a function of the concurrent development of diabetes. We did not conduct sex-specific analyses because there were too few events in some subgroups to calculate stable risk estimates. We estimated the population attributable fraction for diabetes or CVD associated with exposure categories (for instance, the normal weight with MetS category) as the proportion of cases in the exposure category ϫ [(RRexposure category Ϫ 1)/ RRexposure category)] ϫ 100 (22) . We performed all analyses using SAS (SAS Institute, Cary, NC) and considered a two-sided value of P Ͻ 0.05 to be statistically significant.
Results
Characteristics of the study subjects, stratified by BMI and MetS categories, are displayed in Table 1 . The prevalence of most MetS traits and other diabetes or CVD risk factors increased with increasing BMI in subjects with or without MetS, although the trend for increasing risk factors was more prominent across BMI categories among subjects without MetS. Thirty-two percent of those with MetS and normal weight were insulin resistant, 34% of obese subjects without MetS were insulin resistant, and 68% of obese subjects with MetS were insulin resistant.
The distributions of study subjects and incident diabetes or CVD events, stratified by BMI and IR categories, are displayed in Table 2 . Overall, of 2902 subjects, 2.6% were normal weight with MetS (resembling the MONW phenotype), and 8.1% were obese without MetS (resembling the MHO phenotype). Only 33.8% of the sample was normal weight and without MetS, and 13.9% were obese with MetS. Among normal-weight subjects, 7.1% had MetS, and among obese subjects, 37.0% did not have MetS. The distribution of BMIrisk categories was similar using IR instead of MetS. For instance, among normal-weight subjects, 7.7% were insulin resistant, and among obese subjects, 44.3% were insulin sensitive.
Over a mean of 7-yr follow-up, 141 subjects developed type 2 diabetes, and over a mean of 11-yr follow-up, 252 experienced a first CVD event, giving an overall cumulative incidence of 4.9% for diabetes and 8.7% for CVD (Table 2) . Among 1056 normal-weight subjects, there were 17 incident diabetes and 63 first CVD events, giving cumulative incidence of 1.6% for diabetes and 6.0% for CVD. Likewise, among overweight subjects, the cumulative incidence was 4.1% for diabetes and 9.4% for CVD and for obese subjects, 11.6% for diabetes and 11.8% for CVD. Unadjusted cumulative incidences of diabetes and CVD in each category are shown in Table 2 , and age-sex-adjusted cumulative incidences of diabetes or CVD stratified by BMI and MetS are shown in Fig. 1 . At each level of BMI, MetS conferred greater risk of diabetes or CVD.
Age-sex-adjusted and multivariable-adjusted RRs for incident type 2 diabetes or CVD associated with BMI, MetS, IR, and their joint effects are displayed in Tables 3 and 4 . Overweight, obesity, MetS, or IR all increased the multivariable RR for incident diabetes by approximately 5-to 7-fold relative to those without these conditions (Table 3) . Subjects with MetS or IR, regardless of level of BMI, were at a significant approximately 4-to 11-fold increased multivariable RR of incident diabetes relative to normal-weight subjects without MetS or IR. Overweight or obese subjects without MetS and overweight, insulin-sensitive subjects were not at increased risk for diabetes. Interestingly, obese, insulinsensitive subjects were at about 3-fold increased risk of diabetes relative to normal-weight subjects without IR, suggesting that obesity is diabetogenic even in the absence of IR.
Obesity, MetS, or IR increased the multivariable RR for incident CVD by approximately 1.6-to 2-fold relative to those without these conditions (Table 4 ). Subjects with MetS or IR, regardless of obesity category, were at about 2-fold increased risk for CVD relative to normal-weight subjects without MetS or IR. Normal-weight subjects with MetS or IR subjects were at 2-to 3-fold increased risk for CVD events. Subjects without MetS or IR, regardless of BMI category (including obese subjects), were not at increased risk for incident CVD relative to normal-weight subjects without MetS or IR.
The normal weight with MetS phenotype was associated with a small age-sex-adjusted population attributable fraction for adverse outcomes, accounting for 2.9% (95% CI, 1.6 -3.3%) of diabetes risk in the population and for 4.4% In a subsidiary analysis that excluded all cases of incident diabetes occurring over follow-up, associations of obesity and MetS or IR with incident CVD remained very similar. For instance, the multivariable risk factor-adjusted RRs for incident CVD after exclusion of incident diabetes were 3.09 (95% CI, 1.69 -5.66; P ϭ 0.0003) for normal-weight subjects with MetS and 1.56 (0.90 -2.68; P ϭ 0.1) for obese subjects without MetS relative to normal-weight subjects without MetS. Finally, P values for first order BMI-by-MetS or BMI-by-IR interaction terms were all P Ն 0.3, suggesting that MetS or IR did not appear to have more than additive effects on the association of obesity with risk of diabetes or CVD.
Discussion
In this study, we addressed the hypothesis that there is heterogeneity in the metabolic risk status of individuals with normal weight, overweight, or obesity. We observed in our community-based sample that there were small numbers of men and women with normal weight who had MetS or IR, resembling the MONW phenotype described by Ruderman and others (4 -8) and modest numbers with obesity but without MetS or IR, resembling the MHO phenotype described by Brochu, Karelis, and others (10 -13). The presence of metabolic risk factors typically associated with obesity augmented risk for incident type 2 diabetes or CVD, regardless of obesity status. It has thus far only been hypothesized that the MONW or MHO phenotypes exist in the community and have differential associations with diabetes or CVD (23) . We observed that the MONW-like phenotype was associated with a 3-to 4-fold risk factor-adjusted RR for diabetes or CVD events, accounting for 2-3% of these events in the population. Not surprisingly, obese individuals with MetS or IR were at the highest RR for type 2 diabetes, were also at risk for CVD, and accounted for 13-44% of these events in the population. Subjects with the MHO-like phenotype did not appear to be at significantly increased risk for CVD and were at lesser risk for diabetes. Overweight conferred risk intermediate between that of normal weight and obesity but only increased risk in the presence of MetS or IR. The results of this study establish that there are BMI-metabolic risk subphenotypes in the community and that the metabolic consequences of elevated BMI are the critical factors that confer risk for type 2 diabetes or CVD associated with fatness. In the presence of the metabolic consequences of obesity, increasing levels of overall obesity added incremental risk for type 2 diabetes, although not for CVD. Conversely, in the absence of metabolic abnormalities, obesity itself did not increase risk for CVD and was a relatively weak risk factor for incident diabetes.
We defined metabolic risk as the presence of the cluster of risk factors defining ATP3 MetS or by the presence of IR. These characteristics are those typically described to be present in MONW subjects and absent in MHO (23) . ATP3 MetS includes visceral adiposity (assessed by a large waist circumference), which has long been known to confer risk for type 2 diabetes or CVD independent of BMI and to be a key determinant of IR and risk factor clustering (24 -35) . However, only 19% of normal-weight subjects with MetS had a large waist circumference and were at increased risk for diabetes or CVD, whereas 75% of obese subjects without MetS subjects had a large waist circumference and were not at increased risk. Conversely, the other recognized diabetes and CVD risk factors that cluster with central adiposity (including low levels of HDL-C and elevated levels of triglycerides, impaired fasting glucose, and hypertension) occurred with relatively high frequency in normal-weight subjects with MetS but not in obese subjects without MetS. This suggests either that these individual traits were responsible for elevated risk or that their aggregate clustering was the risk factor. The latter interpretation is supported by our observation that the prevalence of BMI-metabolic risk subphenotypes and the magnitude of their associated risks for diabetes or CVD were very similar when metabolic risk was defined by the presence of IR rather than MetS (6, 7, 10, 11) . This interpretation is qualified to some degree by the fact that only 32-68% of FOS subjects with ATP3 MetS were insulin resistant. However, IR at any given degree of obesity has been associated with elevated levels of diabetes and CVD risk factors (36) , and dysmetabolism (MetS and diabetes combined) also confers risk for subsequent CVD events independent of BMI (37) . Whether IR underlies the risk factor clustering embodied in ATP3 MetS is the subject of debate (38) . Nonetheless, our data demonstrate that the presence of metabolic risk defined either by risk factor clusters or IR identifies BMI subphenotypes with substantially different levels of risk for consequences traditionally considered to have a simple dose-response relationship with increasing BMI.
Population-based data on the prevalence of BMI subphenotypes are sparse, and different definitions for metabolic risk allow only indirect comparisons. Some data suggest that the MONW-like phenotype is reasonably common, with a prevalence of 3-28% that depends on the specific definition of metabolic risk and the population source (8, 11, 23, 39) . Our data show that in a white community, the prevalence of a MONW-like phenotype is about 3% overall and 7% among those with BMI less than 25 kg/m 2 . The MHO-like phenotype also appears in other studies to be reasonably common, with a prevalence of 11-28% (10, 11, 40, 41) . Our data are consistent, with 8% of the Framingham community overall and 37% of obese individuals having the obese-no MetS phenotype. We extend these data to show that, as hypothesized, normal-weight subjects with MetS but not obese subjects without MetS individuals were at substantially elevated risk for both type 2 diabetes or CVD over 7-11 yr of followup. The interpretation that obese subjects without MetS are really obese and healthy needs to be made with caution, however. Apparently healthy obese subjects may have subclinical vascular disease (42, 43) so that longer follow-up or more careful evaluation of vascular phenotypes may be required for MHO-like subjects to develop adverse health outcomes, including those not considered in this analysis (2) . Furthermore, given that MHO-like subjects were younger than obese subjects with MetS, as these subjects age, they may transition from obese and apparently healthy to obese with risk factor clustering with accompanying increased risk. In addition, we had limited statistical power in the obesewithout MetS group to detect small differences. Because of our sample size, we had only 30 -40% power to detect a difference in the observed proportions at P ϭ 0.05. Although our sample may have had only enough power to detect large risks in the obese-without MetS group, it is clear that these subjects were at substantially lower risk for diabetes or CVD than any of the metabolically higher risk subgroups. Perhaps the greater significance of the prevalence of the obesewithout MetS phenotype is its converse-that most overweight and obese individuals are metabolically high risk and at substantially elevated risk for diabetes or CVD. Physiological data confirm that the combination of obesity and IR confer the greatest elevations in metabolic risk factors and the greatest degree of risk factor clustering (44, 45) . Our findings have one apparent clinical implication. The clinical role of risk factor clustering as codified in the MetS has thus far been unclear (46) , but one use for MetS may be to discriminate the obese high-risk phenotype from the background population of apparently healthy people at all levels of BMI for purposes of diabetes and CVD prevention.
Strengths of our analysis include the examination of a large, community-based sample of men and women across a broad age spectrum and standardized assessment of diabetes and CVD risk factors and outcomes, but there are limitations of our study in addition to those addressed above. We used a definition of metabolic risk restricted to traditional diabetes or CVD risk factors. In the obese-without MetS phenotype, in particular, measurement of subclinical inflammation, endothelial dysfunction, or adiponectin (13, 43, 47, 48) might reveal less than perfect metabolic health. In addition, follow-up longer than 7-11 yr might be required to be certain that obese subjects without risk factors are indeed low risk. Our observation that BMI incrementally increased risk among subjects with MetS or IR suggests that additional factors associated with obesity, but not measured in this study, further account for risk of adverse health consequences associated with increased BMI. In addition, the criteria defining ATP3 MetS are arbitrary; alternate schemes to define metabolic risk may be equally valid and could produce different results (5, 7, 23) . However, analyses using IR to define metabolic obesity gave essentially similar results as for MetS, suggesting that our findings were not an artifact imposed by the ATP3 MetS criteria. Finally, our data cannot be readily generalized to other communities because the distribution of obesity, MetS, and IR is known to vary substantially across different race/ethnicity groups (49) .
In summary, we used normal-weight, overweight, and obese BMI categories and risk factor clustering or IR to define the prevalence of BMI-metabolic risk subphenotypes in a community-based sample. We found that MONW-like and obese-high-risk phenotypes exist and confer increased risk for incident diabetes or CVD. A MHO-like phenotype was also moderately common and did not confer marked increased risk. Risk factor clustering or IR appear to confer the risk for diabetes or CVD commonly associated with elevated BMI. Assessment of metabolic risk, regardless of BMI, appears to identify individuals at increased risk for future development of type 2 diabetes or CVD and who may benefit from interventions to reduce risk.
